Effect of AAF-2-h1L-10 on immune response following toxic degeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in micep.345

• Autorzy: Joniec L. , Ciesielska A. , Gladka A. , Schwenkgrub J. , Sznejder A. , Cudna A. , Hadaczek P. , Bankiewicz K. , Czlonkowska A. , Czlonkowski A.
• Języki publikacji: EN

Abstrakty

EN

Interleukine 10 (IL-10) – an antiinfl ammatory cytokine produced by lymphocytes and mononuclear phagocytes including microglia. IL10 modulates the biological activities of immune cells resulting in a decreased production of pro-infl ammatory mediators including cytokines, chemokines and adhesion molecules. The aim of the present study was to examine the effect of an adeno-associated viral type-2 (AAV2) vector containing human interleukin-10 (hIL-10) gene to evaluation of immune response to the AAV2-hIL-10 (measured as IFN-γ, GFAP and TGFβ mRNA expression) in the murine model of Parkinson’s disease (PD) induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Male C57BL/6 mice 12 months-old were used in this study. MPTP (40 mg/kg) was injected in four intraperitoneal injections at 1-h intervals. AAV2-hIL-10 vector was bilaterally administered into striatum at 14, 21 or 28 days prior to MPTP intoxication. Animals were sacrifi ced by spinal cords dislocation at 7 days following MPTP injection. TGFβ, IFN-γ and GFAP mRNA expression was examined by RT-PCR method. MPTP treatment signifi cantly increased IFN-γ mRNA expression. AAV2-hIL-10 administration strongly increased IFN-γ as well as TGFβ and GFAP (21 and 28 day) gene expression compared to control and MPTP group. Our results point to the necessity of the reinterpretation of the role of the infl ammatory reaction in nerodegenerative processes

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.345

Twórcy

autor

Joniec L.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Ciesielska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Gladka A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Schwenkgrub J.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Sznejder A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Cudna A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Hadaczek P.

• Department of Neurosurgery, University of California San Francisco, San Francisco, CA, USA

autor

Bankiewicz K.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Czlonkowska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Czlonkowski A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland